Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Multiple Myeloma 3Neoplasms 2Hematologic Neoplasms 2Solid Tumors 1Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Carcinoma, Hepatocellular 1Carcinoma 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4Azacitidine 3venetoclax 2fludarabine phosphate 2fludarabine 2ON 01910 2Mycophenolic Acid 2Melphalan 2Filgrastim 2Cyclosporine 2Busulfan 2lonafarnib 1itacitinib 1ilorasertib 1exatecan 1darinaparsin 1cedazuridine 1Whole-Body Irradiation 1Transplantation 1Teriparatide 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Methotrexate 1Mesna 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Glycopeptides 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory, with Excess of Blasts × darinaparsin × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡